[Correspondence] Genetic risk-targeted islet autoantibody screening for presymptomatic type 1 diabetes in adults

The presymptomatic progression of type 1 diabetes is well characterised in children but remains poorly understood in more than 50% of cases that develop in adulthood.1 This knowledge gap is particularly important following the approval in 2022 from the US Food and Drug Administration (FDA) of teplizumab to slow down early type 1 diabetes progression in children and adults, as well as its subsequent approval by the European Medicines Agency (EMA). Studying type 1 diabetes before symptom development is challenging because islet autoantibody screening is required to identify those at risk and type 1 diabetes is rare, occurring in approximately 1 in 200 people.